Oncolytic herpes simplex virus-1 mutant expressing green fluorescent protein can detect and treat peritoneal cancer

Human Gene Therapy

Volumn 15, Issue 6, 2004, Pages 609-618

  Stanziale, Stephen F ^a   Stiles, Brendon M ^a   Bhargava, Amit ^a   Kerns, Scott A ^a   Kalakonda, Nagesh ^a   Fong, Yuman ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GREEN FLUORESCENT PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER CYTODIAGNOSIS; CANCER LOCALIZATION; CARCINOMATOSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; DRUG SENSITIVITY; FLOW CYTOMETRY; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LAPAROSCOPY; PERITONEUM CANCER; PERITONEUM METASTASIS; PROTEIN EXPRESSION; VIRAL GENE THERAPY; VIRUS RECOMBINATION; VIRUS REPLICATION; ANIMAL; CARCINOMA; CELL CULTURE; COMPARATIVE STUDY; CYTOPATHOGENIC EFFECT; GENE THERAPY; GENETICS; MALE; METABOLISM; METASTASIS; MOUSE; MUTATION; NUDE MOUSE; PATHOLOGY; PERITONEUM TUMOR; PHYSIOLOGY; STOMACH TUMOR; TRANSPLANTATION; VIROLOGY;

ANIMALIA; HUMAN HERPESVIRUS 1;

ANIMALS; CARCINOMA; CYTOPATHOGENIC EFFECT, VIRAL; GENE THERAPY; GREEN FLUORESCENT PROTEINS; HERPESVIRUS 1, HUMAN; HUMANS; LAPAROSCOPY; MALE; MICE; MICE, NUDE; MUTATION; PERITONEAL NEOPLASMS; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 6344272778     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303404323142051     Document Type: Article

References (55)

1. ADVANI, S.J., CHUNG, S.M., YAN, S.Y., GILLESPIE, G.Y., MARKERT, J.M., WHITLEY, R.J., ROIZMAN, B., and WEICHSELBAUM, R.R. (1999). Replication- competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res. 59, 2055-2058.
2. ALAUDDIN, M.M., CONTI, P.S., MAZZA, S.M., HAMZEH, F.M., and LEVER, J.R. (1996). 9-[(3-[18F]-fluoro-1-hydroxy-2-propoxy) methyl]guanine ([18F]-FHPG): A potential imaging agent of viral infection and gene therapy using PET. Nucl. Med. Biol. 23, 787-792.
3. ANDREANSKY, S., SOROCEANU, L., FLOTTE, E.R., CHOU, J., MARKERT, J.M., GILLESPIE, G.Y., ROIZMAN, B., and WHITLEY, R.J. (1997). Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 57, 1502-1509.
4. BENNETT, J.J., KOOBY, D.A., DELMAN, K., MCAULIFFE, P., HALTERMAN, M.W., FEDEROFF, H., and FONG, Y. (2000a). Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. J. Mol. Ther. 78, 166-174.
5. BENNETT, J.J., KOOBY, D.A., DELMAN, K., MCAULIFFE, P., HALTERMAN, M.W., FEDEROFF, H., and FONG, Y. (2000b). Antitumor efficacy of regional oncolytic viral therapy for peritoneally disseminated cancer. J. Mol. Med. 78, 166-174.
6. BENNETT, J.J., TJUVAJEV, J., JOHNSON, P., DOUBROVIN, M., AKHURST, T., MALHOLTRA, S., HACKMAN, T., BALATONI, J., FINN, R., LARSON, S.M., FEDEROFF, H., BLASBERG, R., and FONG, Y. (2001). Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer. Nat. Med. 7, 859-863.
7. BOVIATSIS, E.J., PARK, J.S., SENA-ESTEVES, M., KRAMM, C.M., CHASE, M., EFIRD, J.T., WEI, M.X., BREAKEFIELD, X.O., and CHIOCCA, E.A. (1994). Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res. 54, 5745-5751.
8. CAREW, J.F., KOOBY, D., HALTERMAN, M.W., FEDEROFF, H.J., and FONG, Y. (1999). Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytolytic herpes simplex virus type 1 (G207). Hum. Gene Ther. 10, 1599-1606.
9. CHAHLAVI, A., TODO, T., MARTUZA, R.L., and RABKIN, S.D. (1999). Replication-competent herpes simplex virus vector G207 and cisplatin combination therapy for head and neck squamous cell carcinoma. Neoplasia 1, 162-169.
10. CHALFIE, M., TU, Y., EUSKIRCHEN, G., WARD, W.W., and PRASHER, D.C. (1994). Green fluorescent protein as a marker for gene expression. Science 263, 802-805.
11. CHAMBERS, R., GILLESPIE, G.Y., SOROCEANU, L., ANDREANSKY, S., CHATTERJEE, S., CHOU, J., ROIZMAN, B., and WHITLEY, R.J. (1995). Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Natl. Acad. Sci. U.S.A. 92, 1411-1415.
12. CHOU, J., KERN, E.R., WHITLEY, R.J., and ROIZMAN, B. (1990). Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 250, 1262-1266.
13. CHUNG, S.M., ADVANI, S.J., BRADLEY, J.D., KATAOKA, Y., VASHISTHA, K., YAN, S.Y., MARKERT, J.M., GILLESPIE, G.Y., WHITLEY, R.J., ROIZMAN, B., and WEICHSELBAUM, R.R. (2002). The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene Ther. 9, 75-80.
14. CORMACK, B.P., VALDIVIA, R.H., and FALKOW, S. (1996). FACS-optimized mutants of the green fluorescent protein (GFP). Gene 173, 33-38.
15. COUKOS, G., MAKRIGIANNAKIS, A., MONTAS, S., KAISER, L.R., TOYOZUMI, T., BENJAMIN, I., ALBELDA, S.M., RUBIN, S.C., and MOLNAR-KIMBER, K.L. (2000). Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther. 7, 275-283.
16. DROZDZIK, M., QIAN, C., XIE, X., PENG, D., BILBAO, R., MAZZOLINI, G., and PRIETO, J. (2000). Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma. J. Hepatol. 32, 279-286.
17. FEUSSNER, H., KRAEMER, S.J., and SIEWERT, J.R. (1997). [Staging laparoscopy]. Chirurg. 68, 201-209.
18. GAHLEN, J., STERN, J., LAUBACH, H.H., PIETSCHMANN, M., and HERFARTH, C. (1999). Improving diagnostic staging laparoscopy using intraperitoneal lavage of delta-aminolevulinic acid (ALA) for laparoscopic fluorescence diagnosis. Surgery 126, 469-473.
19. GAHLEN, J., PIETSCHMANN, M., PROSST, R.L., and HERFARTH, C. (2001). Systemic vs local administration of delta-aminolevulinic acid for laparoscopic fluorescence diagnosis of malignant intra-abdominal tumors. Experimental study. Surg. Endosc. 15, 196-199.
20. GAHLEN, J., PROSST, R. L., PIETSCHMANN, M., HAASE, T., RHEINWALD, M., SKOPP, G., STERN, J., and HERFARTH, C. (2002). Laparoscopic fluorescence diagnosis for intraabdominal fluorescence targeting of peritoneal carcinosis experimental studies. Ann. Surg. 235, 252-260.
21. GAMBHIR, S.S., BARRIO, J.R., PHELPS, M.E., IYER, M., NAMAVARI, M., SATYAMURTHY, N., WU, L., GREEN, L.A., BAUER, E., MACLAREN, D.C., NGUYEN, K., BERK, A.J., CHERRY, S.R., and HERSCHMAN, H.R. (1999). Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc. Natl. Acad. Sci. U.S.A. 96, 2333-2338.
22. GLORIOSO, J.C., DELUCA, N.A., and FINK, D.J. (1995). Development and application of herpes simplex virus vectors for human gene therapy. Annu. Rev. Microbiol. 49, 675-710.
23. GOLDSTEIN, D.J., and WELLER, S.K. (1988a). Factor(s) present in herpes simplex virus type 1-infected cells can compensate for the loss of the large subunit of the viral ribonucleotide reductase: Characterization of an ICP6 deletion mutant. Virology 166, 41-51.
24. GOLDSTEIN, D.J., and WELLER, S.K. (1988b). Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 62, 196-205.
25. HEID, C.A., STEVENS, J., LIVAK, K.J., and WILLIAMS, P.M. (1996). Real time quantitative PCR. Genome Res. 6, 986-994.
26. HEMMING, A.W., NAGY, A.G., SCUDAMORE, C.H., and EDELMANN, K. (1995). Laparoscopic staging of intraabdominal malignancy. Surg. Endosc. 9, 325-328.
27. JACOBS, A., DUBROVIN, M., HEWETT, J., SENA-ESTEVES, M., TAN, C.W., SLACK, M., SADELAIN, M., BREAKEFIELD, X.O., and TJUVAJEV, J.G. (1999). Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: Implications for non-invasive imaging of transgene expression. Neoplasia 1, 154-161.
28. JACOBS, A., TJUVAJEV, J.G., DUBROVIN, M., AKHURST, T., BALATONI, J., BEATTIE, B., JOSHI, R., FINN, R., LARSON, S.M., HERRLINGER, U., PECHAN, P.A., CHIOCCA, E.A., BREAKEFIELD, X.O., and BLASBERG, R.G. (2001). Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res. 61, 2983-2995.
29. JAMIESON, A.T., GENTRY, G.A., and SUBAK-SHARPE, J.H. (1974). Induction of both thymidine and deoxycytidine kinase activity by herpes viruses. J. Gen. Virol. 24, 465-480.
30. JERBY, B.L., and MILSOM, J.W. (1998). Role of laparoscopy in the staging of gastrointestinal cancer. Oncology (Huntingt.) 12, 1353-1360.
31. KOOBY, D.A., CAREW, J.F., HALTERMAN, M.W., MACK, J.E., BERTINO, J.R., BLUMGART, L.H., FEDEROFF, H.J., and FONG, Y. (1999a). Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207). FASEB J. 13, 1325-1334.
32. KOOBY, D.A., CAREW, J.F., HALTERMAN, M.W., MACK, J.E., BERTINO, J.R., BLUMGART, L.H., FEDEROFF, H.J., and FONG, Y. (1999b). Oncolytic viral therapy for human colorectal cancer and liver metastases using a multimutated herpes simplex virus type-1 (G207). FASEB. J. 6, 499-504.
33. KUCHARCZUK, J.C., RANDAZZO, B., CHANG, M.Y., AMIN, K.M., ELSHAMI, A.A., STERMAN, D.H., RIZK, N.P., MOLNAR-KIMBER, K.L., BROWN, S.M., MACLEAN, A.R., LITZKY, L.A., FRASER, N.W., ALBELDA, S.M., and KAISER, L.R. (1997). Use of a "replication-restricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Res. 57, 466-471.
34. LONGNECKER, R., CHATTERJEE, S., WHITLEY, R.J., and ROIZMAN, B. (1987). Identification of a herpes simplex virus 1 glycoprotein gene within a gene cluster dispensable for growth in cell culture. Proc. Natl. Acad. Sci. U.S.A. 84, 4303-4307.
35. LORENZ, R., KRESTIN, G.P., and NEUFANG, K.F. (1990). [Diagnosis and differential diagnosis of a peritoneal carcinosis. Conventional techniques, sonography, computed tomography, magnetic resonance tomography]. Radiologe 30, 477-480.
36. LUOH, S.M., DI MARCO, F., LEVIN, N., ARMANINI, M., XIE, M.H., NELSON, C., BENNETT, G.L., WILLIAMS, M., SPENCER, S.A., GURNEY, A., and DE SAUVAGE, F.J. (1997). Cloning and characterization of a human leptin receptor using a biologically active leptin immunoadhesin. J. Mol. Endocrinol. 18, 77-85.
37. MAKINEN, K., LOIMAS, S., WAHLFORS, J., ALHAVA, E., and JANNE, J. (2000). Evaluation of herpes simplex thymidine kinase mediated gene therapy in experimental pancreatic cancer. J. Gene Med. 2, 361-367.
38. MARKERT, J.M., MEDLOCK, M.D., RABKIN, S.D., GILLESPIE, G.Y., TODO, T., HUNTER, W.D., PALMER, C.A., FEIGENBAUM, F., TORNATORE, C., TUFARO F., and MARTUZA, R.L. (2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther. 7, 867-874.
39. MARTUZA, R.L., MALICK, A., MARKERT, J.M., RUFFNER, K.L., and COEN, D.M. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854-856.
40. MIGLIAVACCA, M., BAZAN, V., MATURI, N., MORELLO, V., DARDANONI, G., BAZAN, P., MODICA, G., ALBANESE, I., LA FARINA, M., TOMASINO, R.M., and RUSSO, A. (1997). Flow cytometric S-phase fraction as an independent prognostic indicator in colorectal liver metastases. Eur. J. Histochem. 41(Suppl 2), 137-138.
41. MINETA, T., RABKIN, S.D., YAZAKI, T., HUNTER, W.D., and MARTUZA, R.L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1, 938-943.
42. NAKANO, K., TODO, T., CHIJIIWA, K., and TANAKA, M. (2001). Therapeutic efficacy of G207, a conditionally replicating herpes simplex virus type 1 mutant, for gallbladder carcinoma in immunocompetent hamsters. Mol. Ther. 3, 431-437.
43. PAQUIN, A., JAALOUK, D.E., and GALIPEAU, J. (2001). Retrovector encoding a green fluorescent protein-herpes simplex virus thymidine kinase fusion protein serves as a versatile suicide/reporter for cell and gene therapy applications. Hum. Gene Ther. 12, 13-23.
44. SHIMAMURA, T., NAKAJIMA, Y., UNE, Y., NAMIENO, T., OGASAWARA, K., YAMASHITA, K., HANEDA, T., NAKANISHI, K., KIMURA, J., MATSUSHITA, M., SATO, N., and UCHINO, J. (1997). Efficacy and safety of preoperative percutaneous transhepatic portal embolization with absolute ethanol: A clinical study. Surgery 121, 135-141.
45. TJUVAJEV, J.G., STOCKHAMMER, G., DESAI, R., UEHARA, H., WATANABE, K., GANSBACHER, B., and BLASBERG, R.G. (1995). Imaging the expression of transfected genes in vivo. Cancer Res. 55, 6126-6132.
46. TJUVAJEV, J.G., AVRIL, N., OKU, T., SASAJIMA, T., MIYAGAWA, T., JOSHI, R., SAFER, M., BEATTIE, B., DIRESTA, G., DAGHIGHIAN, F., AUGENSEN, F., KOUTCHER, J., ZWEIT, J., HUMM, J., LARSON, S. M., FINN, R., and BLASBERG, R. (1998). Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography. Cancer Res. 58, 4333-4341.
47. TJUVAJEV, J.G., CHEN, S.H., JOSHI, A., JOSHI, R., GUO, Z.S., BALATONI, J., BALLON, D., KOUTCHER, J., FINN, R., WOO, S.L., and BLASBERG, R.G. (1999). Imaging adenoviral-mediated herpes virus thymidine kinase gene transfer and expression in vivo. Cancer Res. 59, 5186-5193.
48. WONG, R.J., JOE, J.K., KIM, S.H., SHAH, J.P., HORSBURGH, B., and FONG, Y.M. (2002). Oncolytic herpesvirus effectively treats murine squamous cell carcinoma and spreads by natural lymphatics to treat sites of lymphatic metastases. Hum. Gene Ther. 13, 1213-1223.
49. YANG, M., BARANOV, E., JIANG, P., SUN, F.X., LI, X.M., LI, L., HASEGAWA, S., BOUVET, M., AL TUWAIJRI, M., CHISHIMA, T., SHIMADA, H., MOOSSA, A.R., PENMAN, S., and HOFFMAN, R.M. (2000a). Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases. Proc. Natl. Acad. Sci. U.S.A. 97, 1206-1211.
50. YANG, M., BARANOV, E., MOOSSA, A.R., PENMAN, S., and HOFFMAN, R.M. (2000b). Visualizing gene expression by whole-body fluorescence imaging. Proc. Natl. Acad. Sci. U.S.A. 97, 12278-12282.
51. YASHIRO, M., CHUNG, Y.S., NISHIMURA, S., INOUE, T., and SOWA, M. (1996). Peritoneal metastatic model for human scirrhous gastric carcinoma in nude mice. Clin. Exp. Metastasis 14, 43-54.
52. YAZAKI, T., MANZ, H.J., RABKIN, S.D., and MARTUZA, R.L. (1995). Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 55, 4752-4756.
53. YOON, S.S., NAKAMURA, H., CARROLL, N.M., BODE, B.P., CHIOCCA, E.A., and TANABE, K.K. (2000). An oncolytic herpes simplex virus type 1 selectively destroys diffuse liver metastases from colon carcinoma. FASEB J. 14, 301-311.
54. ZAGER, J.S., DELMAN, K.A., MALHOTRA, S., EBRIGHT, M.I., BENNETT, J.J., KATES, T., HALTERMAN, M., FEDEROFF, H., and FONG, Y. (2001). Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer. Mol. Med. 7, 561-568.
55. ZALOUDIK, J., VAGUNDA, V., DRAHOKOUPILOVA, M., JANAKOVA, L., TALAC, R., KALABIS, J., and SHEARD, M. (1997). Biomarkers for predicting response to regional chemo-immunotherapy in liver metastases from colorectal carcinoma. Int. J. Immunopharmacol. 19, 481-485.